Caspofungin: Difference between revisions
(edited dosage forms, strengths, trade name) |
|||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Antifungal]], particularly used for [[aspergillosis]] and [[candidiasis]] | *Type: [[Antifungal]], particularly used for [[aspergillosis]] and [[candidiasis]] | ||
*Dosage Forms: | *Dosage Forms: powder for injection | ||
*Dosage Strengths: 50mg/vial, 70mg/vial | |||
*Routes of Administration: IV | *Routes of Administration: IV | ||
*Common Trade Names: | *Common Trade Names: Cancidas | ||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 00:33, 12 October 2017
Administration
- Type: Antifungal, particularly used for aspergillosis and candidiasis
- Dosage Forms: powder for injection
- Dosage Strengths: 50mg/vial, 70mg/vial
- Routes of Administration: IV
- Common Trade Names: Cancidas
Adult Dosing
- 50-150 mg IV daily
Pediatric Dosing
3 months or older
- 50-70 mg/m(2) daily
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Erythema multiforme, Stevens-Johnson syndrome
- Pancreatitis, hepatic failure
- Sepsis
- Nephrotoxicity
- Pleural effusion, respiratory distress
- Angioedema
Common
- Hypotension
- Rash
- Diarrhea
- Histaminergic reaction (flushing, warmth, pruritus)
- Transaminitis
- Fever
Pharmacology
- Half-life: 13-15 hours
- Metabolism: spontaneous degradation, hydrolysis and N-acetylation
- Excretion: Fecal, renal
Mechanism of Action
- Inhibits beta (1,3)-D-glucan synthesis in fungal cell wall